Abstract
IN THE WAKE OF CALLS FOR THE US Food and Drug Administration (FDA) to discourage the use of cold and cough medicines for children younger than 6 years, the makers of such products have agreed to change the products’ labels, the second labeling change in about a year. In October, the Consumer Healthcare Products Association (CHPA), a group that represents the manufacturers of over-the-counter cold and cough products, announced that its members would voluntarily revise the labels of children’s cold and cough medicines to indicate that the products should not be used in children younger than 4 years. The group also added a warning to the label of products containing antihistamines that they should not be used to sedate children. The announcement came within days of an October 2 hearing hosted by the FDA in which many physicians, public health officials, and consumer advocates urged the agency to take action to prevent the marketing of these medicines to children, particularly those younger than 6 years. The agency supported the industry’s proposal to relabel the products. The agency said it will continue its review of the safety of cold and cough medicines for children of all ages. Although the FDA has been criticized for the pace of its review of these products, John Jenkins, MD, director of the FDA’s Office of New Drugs, said the agency is concerned that removal of all children’s cold and cough products from the market could have unintended negative consequences, such as the possibility that some parents might give their children adult cold and cough products instead.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.